Your cart is empty.
Tecan uses cookies to improve our website. By continuing to browse our website, you accept our cookie policy.
Tecan uses cookies to improve our website. By continuing to browse our website, you accept our cookie policy.
| June 24, 2015 | ||||
Automated PBMC isolation for biobanking with Tecan’s Freedom EVO® |
||||
Männedorf, Switzerland, June 24, 2015 – IBBL (Integrated BioBank of Luxembourg) has developed the world’s first fully automated technique for the isolation of viable peripheral blood mononuclear cells (PBMCs) using a Freedom EVO® workstation. Dr Fay Betsou, Chief of Biospecimen Science, explained: “PBMCs are of increasing interest for vaccine development and validation, and we have seen a steady increase in requests for PBMC-based functional assays. These cells – primarily lymphocytes and monocytes – are traditionally extracted manually using a laborious and time-consuming Ficoll-Paque method, taking a technician approximately four hours to isolate PBMCs from 10 samples.” |
||||
|
For more information please contact Tecan Trading AG Tel +41 (0)44 922 81 11 
About Tecan Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. The company specializes in the development, production and distribution of automated workflow solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, and forensic and diagnostic laboratories. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2014, Tecan generated sales of CHF 400 million (USD 437 million; EUR 331 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191). 
About IBBL The IBBL (Integrated BioBank of Luxembourg) Institute is a biobank dedicated to supporting biomedical research for the benefit of patients. The mission of IBBL is to provide high-quality biospecimens and associated data, foster scientific excellence, catalyse partnerships and support research that translates scientific discoveries into new healthcare solutions. IBBL is an integrated research infrastructure, compliant with international quality standards, offering biobanking services, including the collection, processing, analysis and storage of biological samples and associated data. In addition, IBBL carries out research to optimise biospecimen processing and certify biospecimen quality. IBBL is an autonomous institute, organised within the Luxembourg Institute of Health (LIH). For more information, please visit our corporate website (www.ibbl.lu) or our public website (www.biobank.lu) |